Innovative Gene Therapy for
Multiple Sclerosis
Multiple sclerosis is a multifactorial condition, and the development of a successful therapy requires not only considering the full spectrum of biological disturbances (factors) associated with the disease, across molecular, cellular, systemic levels, but also ranking them by significance with a mandatory assessment of the scientific and experimental evidence pertaining to each.
​The pathogenetic concept adopted in this project accords with mainstream understanding: the cognitive impairments, sensory deficits, coordination and balance problems, visual disturbances, and other manifestations of MS result from a malfunctioning immune system that attacks the body’s own tissues—namely, the myelin sheath of neurons. This demyelination slows or completely disrupts signal conduction along neural pathways, giving rise to the wide spectrum of neurological symptoms. As the disease progresses, neuronal loss and the breakdown of neural networks lead to severe disability.